Orthogonal Detection Techniques to Provide More Complete Characterization of an Oral Drug

Importance of the topic

The accurate identification and characterization of pharmaceutical compounds is critical for quality control and regulatory compliance in drug development and manufacturing. Orthogonal detection techniques provide complementary data that enhance confidence in component identification, detect co-eluting or isobaric species, and improve overall method robustness.

Study objectives and overview

This work demonstrates the integration of photodiode array (PDA) and mass detection (QDa) within a UPLC platform to achieve comprehensive characterization of seven angiotensin II receptor blockers (ARBs) and related impurities. The approach highlights the benefit of combining UV spectral information with mass-to-charge data in a single analysis.

Methodology and instrumentation

The separation was performed on an Acquity UPLC HSS T3 column (1.8 µm, 2.1 × 100 mm) maintained at 50 °C under isocratic conditions (60 % methanol, pH 2.99). A flow rate of 0.55 mL/min and injection volume of 0.7 μL were applied. Detection was carried out using a PDA detector (200–400 nm, 254 nm) and a QDa mass detector (ESI+ full scan m/z 100–700, SIR for specific m/z values).

Main results and discussion

The combined UPLC-PDA-QDa system resolved seven ARB components with retention times from 0.672 to 2.699 min. Mass detection provided unambiguous m/z identification, while UV spectra distinguished isobaric compounds. Key findings include:

• Telmisartan related compound A (RT 0.672 min, m/z 305.3)
• Irbesartan related compound A (RT 1.437 min, m/z 447.5)
• Telmisartan impurity E (RT 1.656 min, m/z 429.5)
• Telmisartan related compound B (RT 2.017 min, m/z 515.5)
• Irbesartan standard (RT 2.198 min, m/z 429.5)
• Valsartan standard (RT 2.423 min, m/z 436.5)
• Telmisartan standard (RT 2.699 min, m/z 515.5)

The UV overlay revealed identical spectra for certain isobaric pairs; mass detection confirmed their identities. Empower 3 mass analysis view enabled simultaneous visualization of chromatograms, UV spectra, and mass spectra.

Benefits and practical applications

Integrating orthogonal detectors in a single run streamlines method development and routine QC by:

• Confirming peak identities without separate injections of standards
• Detecting co-eluting or isomeric compounds via UV spectral and mass differences
• Improving throughput by consolidating data acquisition and analysis

Future trends and applications

Advances may include higher-resolution mass detectors, expanded spectral libraries, and automated data interpretation algorithms. These enhancements will further simplify complex mixture characterization and support regulatory compliance.

Conclusion

The combined UPLC-PDA-QDa platform offers a robust, efficient approach for comprehensive characterization of pharmaceutical compounds. Orthogonal detection delivers complementary data that enhance component identification, resolve analytical challenges, and support quality assurance.